Ascelia Pharma AB (publ) (ticker: ACE), a biotech company focused on improving the life of people living with rare cancer conditions, today announced the filing of a new patent application for its first-in-class liver imaging drug Orviglance®.
The patent application covers innovations related to packaging and manufacturing of Orviglance, which includes improving the usability for patients and healthcare professionals. Subject to approval and grant, the patent is expected to further strengthen the market position and future potential of Orviglance.
“This patent application reflects our strategy to strengthen our Orviglance franchise and maximize long-term value”, said Magnus Corfitzen, CEO of Ascelia Pharma.